How does the NMCares programme aim to alleviate treatment costs for breast cancer patients?

Question

Accepted Answer

The NMCares Targeted Therapy Welfare Programme aims to alleviate treatment costs for HER2-positive breast cancer patients through a co-payment model and existing financial aid initiatives.

The NMCares Targeted Therapy Welfare Programme, a collaboration between Nilai Medical Centre and Roche Malaysia, is designed to provide financial assistance to individuals diagnosed with HER2-positive breast cancer. This initiative operates through Roche Cares, a tripartite co-payment model that enables patients to access essential targeted therapy at a reduced cost, potentially allowing eligible individuals to save over half of their overall treatment expenses. This programme builds upon Nilai Medical's established Cancer Assistance Programme (NMCares), which was initiated in July 2020 with the National Cancer Society Malaysia and had allocated RM8 million over a five-year period to support cancer patient treatments.
Financial Aid for HER2-Positive Breast Cancer Patients

The newly launched NMCares Targeted Therapy Welfare Programme specifically targets HER2-positive breast cancer, a subtype that affects approximately one in five breast cancer patients globally and is characterised by rapid growth. The programme's core mechanism is the Roche Cares co-payment model, which effectively subsidises the cost of targeted therapies. This approach is crucial as HER2-targeted treatments have significantly improved the prognosis for this aggressive form of cancer, making them vital for patient outcomes.
Expanded Support Through Existing Programmes

This targeted initiative is an extension of Nilai Medical's broader commitment to cancer patient support. The original NMCares programme, established in partnership with the National Cancer Society Malaysia, has been instrumental in providing financial aid since its inception in July 2020. With an initial allocation of RM8 million spread over five years, this programme has already assisted numerous cancer patients in accessing necessary medical interventions. The collaboration with Roche Malaysia allows for a more specific focus on HER2-positive breast cancer patients within the existing framework.
Addressing Financial Barriers and Public-Private Partnerships

The programme's launch comes at a time when financial strain on patients is a significant concern, exacerbated by the challenges of the Covid-19 pandemic. By reducing the financial burden associated with targeted therapies, the NMCares Targeted Therapy Welfare Programme seeks to alleviate a major worry for financially challenged breast cancer patients. The Deputy Health Minister, Datuk Dr Noor Azmi Ghazali, has acknowledged the importance of such public-private partnerships, highlighting their role in providing peace of mind to patients and potentially easing the load on public healthcare facilities.
Eligibility and Application Process

The NMCares Targeted Therapy Welfare Programme is accessible to Malaysian cancer patients who encounter difficulties in meeting their treatment costs. Nilai Medical has established a dedicated team responsible for assessing each applicant's situation and verifying their eligibility for aid. This ensures that the financial assistance is directed towards those most in need, providing a crucial lifeline for individuals battling HER2-positive breast cancer and facing economic hardship.

Reading history

Hide →

This history is cleared when the page is closed.

How does the NMCares programme aim to alleviate treatment costs for breast cancer patients?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends